CATCH: A Prospective Precision Oncology Trial in Metastatic Breast Cancer. (22nd April 2021)

• Record Type: Journal Article
• Authors: Hlevnjak, Mario; Schulze, Markus; Elgaafary, Shaymaa; Fremd, Carlo; Michel, Laura; Beck, Katja; Pfütze, Katrin; Richter, Daniela; Wolf, Stephan; Horak, Peter; Kreutzfeldt, Simon; Pixberg, Constantin; Hutter, Barbara; Ishaque, Naveed; Hirsch, Steffen; Gieldon, Laura; Stenzinger, Albrecht; Springfeld, Christoph; Smetanay, Katharina; Seitz, Julia; Mavratzas, Athanasios; Brors, Benedikt; Kirsten, Romy; Schuetz, Florian; Fröhling, Stefan; Sinn, Hans-Peter; Jäger, Dirk; Thewes, Verena; Zapatka, Marc; Lichter, Peter; Schneeweiss, Andreas;
• Is Part Of: JCO precision oncology. Volume 5(2021)
• Page Start: 676
• Page End: 686
• Publication Date: 2021-04-22
• Subjects: Precision Medicine; Neoplasms; Pharmacogenetics; Molecular Targeted Therapy; Personalized medicine; Oncology; Pharmacogenomics; Periodical; Periodicals; 616.994
• DOI: 10.1200/PO.20.00248
• Languages: English
• ISSNs: 2473-4284

Abstract

Abstract : PURPOSE: CATCH (Comprehensive Assessment of clinical feaTures and biomarkers to identify patients with advanced or metastatic breast Cancer for marker driven trials in Humans) is a prospective precision oncology program that uses genomics and transcriptomics to guide therapeutic decisions in the clinical management of metastatic breast cancer. Herein, we report our single-center experience and results on the basis of the first 200 enrolled patients of an ongoing trial. METHODS: From June 2017 to March 2019, 200 patients who had either primary metastatic or progressive disease, with any number of previous treatment lines and at least one metastatic site accessible to biopsy, were enrolled. DNA and RNA from tumor tissue and corresponding blood-derived nontumor DNA were profiled using whole-genome and transcriptome sequencing. Identified actionable alterations were brought into clinical context in a multidisciplinary molecular tumor board (MTB) with the aim of prioritizing personalized treatment recommendations. RESULTS: Among the first 200 enrolled patients, 128 (64%) were discussed in the MTB, of which 64 (50%) were subsequently treated according to MTB recommendation. Of 53 evaluable patients, 21 (40%) achieved either stable disease (n = 13, 25%) or partial response (n = 8, 15%). Furthermore, 16 (30%) of those patients showed improvement in progression-free survival of at least 30% while on MTB-recommended treatment compared with the progression-free survival of the previous treatment line. CONCLUSION: The initial phase of this study demonstrates that precision oncology on the basis of whole-genome and RNA sequencing is feasible when applied in the clinical management of patients with metastatic breast cancer and provides clinical benefit to a substantial proportion of patients.